Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 10, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Highlights Upcoming Major Milestones

Clinical results expected 1H 2020 from BXCL501 Phase 3 trial for acute treatment of agitation in Schizophrenia and Bipolar patients Data also expected from BXCL501 Phase 1b in 1H 2020 for acute...
September 26, 2019 09:11 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced the...
September 25, 2019 16:27 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

NEW HAVEN, Conn., Sept. 25, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, today announced that...
September 18, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices

Neuropsychiatric patients are vulnerable to multiple agitation episodes; Alzheimer’s dementia patients specifically require integrated patient management solutions Expands market potential of...
September 04, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)

Expansion of clinical development for BXCL701 program planned in hematological malignancies, beyond solid tumors (Pancreatic and tNEPC) Confirmation and further extension of key findings in Nature...
August 20, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501

Expands clinical development of BXCL501 program for treatment of alcohol and substance use disorders (“ASUD”), related to post-traumatic stress disorder (“PTSD”) and traumatic brain injury (“TBI”) ...
August 06, 2019 07:30 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

BXCL501 met primary endpoint in agitated schizophrenia patients with clinically meaningful, rapid and durable reduction in PEC score maintained for 4 to 6 hours in its Phase 1b, randomized, double...
July 31, 2019 08:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth Conference

NEW HAVEN, Conn., July 31, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present...
July 30, 2019 16:01 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update

NEW HAVEN, Conn., July 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), today announced that the Company is scheduled to release its second quarter and half year 2019...
July 22, 2019 06:00 ET | Source: BioXcel Therapeutics, Inc.

BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia

Statistically significant mean reduction in PEC score at two hours compared to placebo following a single dose of 180 mcg (p<0.0001), with rapid and durable reductions in PEC score maintained for 4...